These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17761990)

  • 1. Human epidermal growth factor receptor 2 testing recommendation.
    Raji A
    J Clin Oncol; 2007 Sep; 25(25):4020-1; author reply 4021-3. PubMed ID: 17761990
    [No Abstract]   [Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2 testing in breast cancer.
    Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
    J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
    [No Abstract]   [Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
    Hameed O; Chhieng D; Adams AL
    J Clin Oncol; 2008 Mar; 26(9):1571. PubMed ID: 18349417
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
    Fitzgibbons P; Washington MK; Murphy D
    Cancer; 2010 Aug; 116(16):3980-1; author reply 3981. PubMed ID: 20564109
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
    Egervari K; Szollosi Z; Nemes Z; Kaczur V
    Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
    Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
    J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
    Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
    Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
    Neven P; Brouckaert O; Van Belle V; Vanden Bempt I; Hendrickx W; Cho H; Deraedt K; Van Calster B; Van Huffel S; Moerman P; Amant F; Leunen K; Smeets A; Wildiers H; Paridaens R; Vergote I; Christiaens MR
    J Clin Oncol; 2008 Apr; 26(10):1768-9; author reply 1769-71. PubMed ID: 18519273
    [No Abstract]   [Full Text] [Related]  

  • 10. Luminal B breast tumors are not HER2 positive.
    Bhargava R; Dabbs DJ
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
    Moelans CB; van Diest PJ
    J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
    [No Abstract]   [Full Text] [Related]  

  • 12. [erbB2 as a prognostic factor of breast cancers].
    Nishimura R; Nagao K; Miyayama H
    Nihon Rinsho; 2000 Apr; 58 Suppl():407-12. PubMed ID: 11026025
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
    Schmidt C
    J Natl Cancer Inst; 2008 May; 100(10):694-5. PubMed ID: 18477795
    [No Abstract]   [Full Text] [Related]  

  • 16. Anthracyclines in the treatment of HER2-negative breast cancer.
    Paik S; Taniyama Y; Geyer CE
    J Natl Cancer Inst; 2008 Jan; 100(1):2-4. PubMed ID: 18159066
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C; Müller S; Noske A; Schneider A
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is prophylactic cranial irradiation a possible option for human epidermal growth factor receptor 2-positive breast cancer?
    Buyukhatipoglu H; Sevinc A; Pehlivan Y; Camci C
    J Clin Oncol; 2007 Apr; 25(10):1292; author reply 1293. PubMed ID: 17401024
    [No Abstract]   [Full Text] [Related]  

  • 19. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.